GlassScriptPhysician profile
Maura Levandowski
NPI 1770053324
$9,363.70
in general payments reported to CMS, 2019-2025
22 companies · $2,717 in 2025
The $2,717 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.97 · 2022: $480 · 2023: $2,140 · 2024: $3,991 · 2025: $2,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,650 · Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,650.00 |
| Food and Beverage | $3,197.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $3,654.91 | 2024 | Tremfya |
| Eli Lilly and Company | $2,250.00 | 2025 | Omvoh |
| Abbvie INC. | $919.40 | 2021-2025 | |
| Janssen Biotech, INC. | $377.21 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $328.13 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $293.56 | 2022-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $273.34 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.79 | 2022-2023 | Xifaxan |
| Ardelyx, INC. | $179.61 | 2023 | Ibsrela |
| Pfizer INC. | $144.34 | 2024 | |
| Genzyme Corporation | $132.84 | 2023 | |
| Intercept Pharmaceuticals, INC. | $127.24 | 2022-2023 | Ocaliva |
| Medtronic, INC. | $105.86 | 2021-2023 | Interstim |
| Regeneron Healthcare Solutions, INC. | $81.42 | 2022-2024 | Dupixent |
| Qol Medical, LLC | $76.68 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.55 | 2022-2023 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $44.56 | 2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $30.55 | 2023 | |
| Alexion Pharmaceuticals, INC. | $24.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.09 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $15.64 | 2023 | Sutab |
| Sandoz INC. | $14.37 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maura Levandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.